3 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow CVAD protocol: new trials by email Literature Review of CVAD protocol trials Research Report on CVAD protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias Venetoclax, Hyper-CVAD - Refractory Acute Leukemia, Relapsed Acute Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-02-18 | 2026-09-15 |
| Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD - Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-11 | 2026-08-10 |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
Burkitt Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
M.D. Anderson Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (3)
Bijal Shah, MD (1) · David McCall, MD (1) · Elias Jabbour, MD (1)